This study explores how safe and effective **Tezepelumab** is for treating adults with moderate to very severe **Chronic Obstructive Pulmonary Disease (COPD)**. COPD is a lung disease that makes it hard to breathe. Participants receive a subcutaneous (under the skin) injection of Tezepelumab or a placebo. A placebo looks like the real treatment but has no active drug. The study lasts between 52 to 76 weeks, with an additional 12-week follow-up period. Participants must be aged 40 to 80, have had COPD for at least a year, and have experienced flare-ups in the past year. They should also be on a specific inhaled therapy. The study excludes those with other major lung diseases or cancers.

• The study lasts up to 88 weeks, including follow-up.
• Participants receive monthly injections.
• Should have prior COPD treatment and experienced recent exacerbations.

If you qualify and join, you'll help researchers understand how well Tezepelumab works for COPD treatment.